Posts

Showing posts with the label stockrecommendations

largecap stocks: For volatile market conditions: 5 largecap stocks from different sectors with upside potential of up to 29%

Image
[hfe_template id='11223'] [ad_1] Synopsis Once again on Wednesday, there was a lesson for all who think that bull markets don't see volatility. All of sudden there was a sharp dip in Nifty and other broader market indices, except bank nifty which was trading in green thanks to the fact its largest constituent HDFC bank was trading in green. When valuations are high, volatility never gives notice before coming so one should always be prepared for it. Another point to be watched, if the frequency of the volatile phase increases and if it starts to happen every other fortnight, it might be an indication of profit booking. There is a possibility that as markets inch higher on index levels, there is some sort of rotational profit booking happening. So, it would be better to stay prepared for volatility. Another reason for staying with large caps is that valuations are high in large part of the mid and small caps and they are the ones which might lose more weight if there...

Neither PSU, nor fully private: 7 mid and small cap banks which are hybrid model in many ways with an upside potential of up to 41 %

Image
[hfe_template id='11223'] [ad_1] Synopsis Banking, a sector where in the last two years winds have blown into as many directions as one could have imagined. Normalization of valuation in large private sector banks, a clean up in the PSU space. Then there is a third set of banks, where probably all these things happened. Right from tech upgrade, clean up of balance sheet, expansion of network and partial upgrade of valuation. In the last few days, there has been a debate about PSU and private banks. The third set of banks is once again not finding much mention on the street. But the fact is that over the last few years, they have been improving their performance, but because they are not majorly in the eyes of either policy makers or the street, they tend to get less attention. The reason for the improvement is a simple one, when RBI makes a change in law, it applies equally to all, whether it is HDFC banks or SBI or a bank which is neither private nor public and are some...

Hot Stocks: Brokerages on Escorts & SBI; CLSA downgrades Sula

Image
[hfe_template id='11223'] [ad_1] Brokerage JPMorgan maintained an overweight rating on SBI and Macquarie upgraded Escorts to outperform. CLSA downgraded Sula to underperform while maintaining a sell on Asian Paints post Q4 results. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: JPMorgan on SBI: Overweight| Target Rs 1000 JPMorgan maintained an overweight rating on SBI but raised the target price to Rs 1000 from Rs 725 earlier. The FY24 print shows that the growth and the return on equity (ROE) gap to private banks has closed out. The global investment bank expects a similar dynamic to sustain this year as well.Positioning is enviable with a growth pick-up in corporate loans, low pressure on opex, and a favourable asset quality environment.Despite potentially lower recovery income in FY25, we think the bank can continue to print 1%+ ROA. CLSA on Sula: Underperform| Target Rs 515 CLSA downgraded Sula to underperform from a...

Hot Stocks: Brokerage view on Max Financials, Pidilite, JSW Energy and PB Fintech

Image
[hfe_template id='11223'] [ad_1] Brokerage firm Morgan Stanley has an Equal Weight rating on PB Fintech, Jefferies recommended a buy on JSW Energy, Goldman Sachs maintained a buy on Pidilite Industries and UBS has a buy on Max Financials. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Morgan Stanley on PB Fintech: Equal Weight| Target Rs 1010 Morgan Stanley maintained an Equal Weight rating on PB Fintech with a target price of Rs 1010. The beat was led by much stronger insurance business. The core business beat was led by strong insurance new business growth.Disbursement growth was weaker due to tighter credit supply. Adjusted EBITDA margin reached a new high.Investor focus will be on the sustainability of premium momentum and a pickup in the credit business.Jefferies on JSW Energy: Buy| Target Rs 690 Jefferies maintained a buy rating on JSW Energy but raised the target price to Rs 690 from Rs 600 earlier. The profitabil...

Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 49%

Image
[hfe_template id='11223'] [ad_1] Synopsis It is after a long period of time that on Friday bears are visible in both segments of market, in the broader market like indices like Nifty and Sensex, but also in the broader market breadth. There is no major follow up in today's trading session, but given the fact valuations are expensive it would be better to still be cautious. In such times, stocks where there are some improvements in the business operating matrix that tend to weather the storm better. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame. In bullish markets, the street tends to ignore valuations. But when the market corrects, like the way it did on Friday and is happening in some of the stocks which are relat...

Hot Stocks: Brokerages on RIL, Entero Healthcare, Natco Pharma and Persistent Systems

Image
[hfe_template id='11223'] [ad_1] Brokerage Nomura maintained a neutral rating on Persistent Systems, Investec maintained a buy on Natco Pharma and initiated a buy on Entero Healthcare. CLSA downgraded RIL to outperform. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Nomura on Persistent Systems: Neutral| Target Rs 3400 Nomura maintained a neutral rating on Persistent Systems but slashed the target price to Rs 3400 from Rs 3800 earlier. Growth remains resilient and margins disappointed. Deal wins have moderated. Going forward, strong execution is likely to help deliver industry-leading growth. Margin expansion aspiration pushed out due to continued macro weakness. The global investment bank reduced earnings per share (EPS) estimates by 9-11% over FY25-26. Investec on Natco Pharma: Buy| Target Rs 1200 Investec maintained a buy rating on Natco Pharma but raised the target price to Rs 1200 from Rs 710 earlier.It has the abil...